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Reductive cyclization3-(4,5-Dimethoxy-2-nitrophenyl)coumarins bearing various substituents on the benzene ring of the cou-
marin system have been prepared from salicylaldehydes and 2-(4,5-dimethoxy-2-nitrophenyl)acetoni-
trile by means of the Perkin condensation. Further cyclization of these 3-aryl coumarins through the
microwave-assisted Cadogan reaction afforded the corresponding indolo[3,2-c]coumarins in good to
excellent yields.
 2013 Elsevier Ltd. All rights reserved.N
(Het)Ar1
(Het)Ar1The deoxygenation of C-nitroso- or C-nitro-substituted (het-
ero)arenes by the action of trivalent phosphorus-containing com-
pounds (e.g. triethyl phosphite and triphenylphosphine) occurs
via the Cadogan reaction.1 When conducted in an intramolecular
sense, N-containing heterocycles are formed. It has been assumed
that the transformation takes place through a nitrene-type inter-
mediate (Scheme 1).2 The Cadogan reaction is a simple and conve-
nient synthetic route to indoles, carbazoles, and other condensed
derivatives of pyrroles, imidazoles, pyrazoles, and triazoles.3
This reaction has been improved by using microwave irradia-
tion instead of conventional reﬂux for several hours. This has led
to reduced reaction times of two minutes at best, and increased
yields of the major products.4 Although a number of aromatic
and heteroaromatic nitro compounds have been used successfully
in the Cadogan cyclization, there are no reports in the literature on
using coumarin derivatives in this reaction.
Coumarins represent an important family of oxygen-containing
fused heterocycles, which are widely distributed in Nature, espe-
cially in plants. Natural coumarins and their synthetic analogs
exhibit a wide range of physiological activities, such as anti-
oxidant,5a antifungal,5b antihelmintic,5c anticoagulant (warfarin),5d
antibacterial (novobiocin),5e and antiviral5f properties, including
anti-HIV5g (lamellarines) and anti-HCV5h activities (Fig. 1). Also,coumarin derivatives are important as ﬂuorescent indicators, opti-
cal brighteners, and photosensitizers or dyes for lasers and DSSC
(dye-sensitized solar cell).6,7 The development of novel synthetic
approaches to coumarin derivatives is of signiﬁcant synthetic
importance.
Indolo[3,2-c]coumarins[chromeno[4,3-b]indol-6(11H)-ones]
are nitrogen-containing analogs of naturally occurring compounds
known as coumestans (benzofuro[3,2-c]chromen-6-one), exam-
ples of which include coumestrol, wedelolactone, and plicadin,
which are found in various plants (Fig. 2).
Since many coumestans possess estrogenic,8a antitumor,8b and
antihepatotoxic8c activities, the development of synthetic
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Figure 2. Naturally occurring coumestans.
R. A. Irgashev et al. / Tetrahedron Letters 54 (2013) 5734–5738 5735approaches to new derivatives and close structural analogs of
coumestans, as well as elucidation of their pharmacological prop-
erties are worthwhile.
In this Letter, we report a novel and convenient synthetic
approach to indolo[3,2-c]coumarins based on the microwave-
assisted Cadogan cyclization of 3-(2-nitroaryl)-substituted
coumarins.
It should be noted that a number of synthetic routes to indo-
lo[3,2-c]coumarins have been described in the literature, including
copper-catalyzed cyclization of 2-(2-halophenyl)indole-3-carbox-
ylic acids 1,9a palladium-catalyzed carbonylation/lactonization of
2-(2-acetoxyphenyl)-3-iodoindoles 2,9b thermal cyclization of
4-azido-3-arylcoumarins 3,9c and dehydrogenation of 4-amino-3-
arylcoumarins 49d (Scheme 2). These methods utilize derivatives
of coumarin and indole, which have to be prepared in several steps.
In contrast, our approach to the synthesis of indolo[3,2-c]couma-
rins can be realized in two steps from commercially available
reagents. As a result of the Perkin condensation of salicylaldehydes
5a–h with 2-(4,5-dimethoxy-2-nitrophenyl)acetonitrile, a number
of 3-(4,5-dimethoxy-2-nitrophenyl)coumarins 6a–h have been
obtained.10 This transformation was carried out in ethanol in the
presence of piperidine as the catalyst, and the intermediate imines
A were hydrolyzed with sulfuric acid without isolation (see
Scheme 3, Table 1). Coumarins 6a–g were obtained in 83–98%
yields and required no further puriﬁcation after ﬁltration (purityO
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Scheme 2. Synthetic routes toassessed by 1H NMR). An exception was coumarin 6h for which
crystallization from DMF was necessary to obtain the target prod-
uct, albeit in a relatively low yield of 27%.
The starting 2-(4,5-dimethoxy-2-nitrophenyl)acetonitrile re-
quired for the Perkin condensation was prepared by nitration of
homoveratronitrile with nitric acid in glacial acetic acid.11
Attempts to synthesize coumarins 6 by means of the Perkin con-
densation of salicylaldehydes with ethyl 2-(4,5-dimethoxy-2-
nitrophenyl)acetate in the presence of piperidine as the catalyst
failed, even with a stronger base, such as potassium tert-butoxide.
The structures of coumarins 6 were conﬁrmed by elemental anal-
ysis and 1H, 13C NMR, and IR spectroscopy. However, the 13C
NMR spectra of coumarins 6f,g could not be obtained due to the
poor solubility of these compounds in deuterated solvents. The
structures of coumarins 6 were established unequivocally by
X-ray crystallographic analysis, performed on compound 6a
(Fig. 3).12
The second step in the synthesis of indolo[3,2-c]coumarins was
reductive cyclization of compounds 6. We decided to study the
microwave-assisted Cadogan reaction for the synthesis of indo-
lo[3,2-c]coumarins 7, as it was reported earlier that the use of
the microwave-assisted technique was effective for various sub-
strates.4b The results obtained demonstrate that the microwave-
assisted Cadogan reaction was successful for the preparation of
compounds 7. Optimization of the temperature, time, andO
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Scheme 4. The Cadogan cyclization of coumarin 6a.
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Figure 3. Mercury13 representation of the X-ray crystal structure of 6a. Thermal
ellipsoids at 50% probability.
Table 1
Yields and melting points of coumarins 6
Salicylaldehyde R1 R2 R3 Coumarin Yield (%) Mp (C)
5a H H H 6a 98 232–233
5b OMe H H 6b 94 236–237
5c OMe Br H 6c 92 254–255
5d H OMe H 6d 87 232–234
5e Br Br H 6e 83 237–238
5f H Cl H 6f 85 274–275
5g H Br H 6g 95 278–280
5h H Benzo[f] 6h 27 282–284
5736 R. A. Irgashev et al. / Tetrahedron Letters 54 (2013) 5734–5738solvents was performed on the synthesis of coumarin 7a.
Triphenylphosphine or triethyl phosphite was used as a reducing
agent in these transformations (see Table 2 and Scheme 4).
It was found that indolo[3,2-c]coumarin 7a was formed in the
highest yield when the reaction mixture was heated at 200 C for
25 min in diglyme under microwave irradiation (Table 2, entry
5). The yields of 7a were slightly different when triphenylphos-
phine or triethyl phosphite was used under the same reaction
conditions.
The optimized conditions for the preparation of 7a were used
for the synthesis of other indolo[3,2-c]coumarins 7.14 However,
triphenylphosphine proved to be unsuitable for the syntheses of
7c–e. Instead, these compounds were obtained in good yields
when triethyl phosphite was used as the reducing agent. Indeed,Table 2
Optimization of the conditions for MW-assisted Cadogan cyclization
Entry Solvent Time (min)
1 1,2-Dichlorobenzene 5
2 1,2-Dichlorobenzene 10
3 1,2-Dichlorobenzene 25
4 DMF 25
5 Diglyme 25
a 1 mmol of 6a, 3 mmol of Ph3P or (EtO)3P and 2.5 ml of an appropriate solvent were
b A mixture of 6a and 7a was obtained with low conversion of the starting material.triethyl phosphite proved to be a more effective reagent for
cyclization of coumarins 6. The exception was coumarin 6h, which
did not undergo cyclization in the presence of triethyl phosphite
(see Scheme 5 and Table 3).
It should be noted that indolo[3,2-c]coumarins 7a–h were ob-
tained in good to excellent yields and in analytically pure form
without the need for further puriﬁcation. All products 7 had very
low solubility in a majority of organic solvents, while their melting
points exceeded 350 C.
Two methods for the further modiﬁcation of indolo[3,2-c]cou-
marin 7a have been studied. Demethylation of compound 7a was
performed with 48% hydrobromic acid under reﬂux to give the cor-
responding dihydroxy derivative 8 in yield of 55%. 11-Substituted
compounds 9a,b were isolated in moderate yields (9a - 33%; 9b -
37%) via alkylation of indolo[3,2-c]coumarin 7a. This synthesis
was carried out in DMF at room temperature in the presence of
sodium tert-butoxide as the base (Scheme 6).
The structure of benzylated derivative 9a was conﬁrmed by
X-ray crystallography (Fig. 4).15 This analysis provided an indirect
proof for the structures of indolo[3,2-c]coumarins 7, in addition to
the 1H and 13C NMR spectral data and elemental analyses.
In summary,wehavedevelopeda convenient andhighlyefﬁcient
two-step synthesis of indolo[3,2-c]coumarins from commercially
available salicylaldehydes bymeans of the Perkin condensation, fol-
lowed by microwave-assisted Cadogan cyclization. Further studiesYield (%) with Ph3Pa Yield (%) with (EtO)3Pa
(6a/7a)b (6a/7a)b
41 67
54 61
0 0
68 71
used.
Table 3
Yields of indolo[3,2-c]coumarins 7 with Ph3P and (EtO)3P
Coumarin R1 R2 R3 Indolo[3,2-c]coumarin Yield (%) with Ph3P Yield (%) with (EtO)3P
6a H H H 7a 68 71
6b OMe H H 7b 68 86
6c OMe Br H 7c 0 92
6d H OMe H 7d 0 89
6e Br Br H 7e 0 73
6f H Cl H 7f 61 82
6g H Br H 7g 64 83
6h H Benzo[f] 7h 58 0
Figure 4. Mercury13 representation of the X-ray crystal structure of 9a. Thermal
ellipsoids at 50% probability.
O O
HN
OMe
OMe
O O
HN
OH
OHRX
NaO t-Bu / DMF
48% HBr
Δ
O O
N
OMe
OMe
R
9a,b 7a 8
RX: PhCH2Cl (9a), n-C6H13Br (9b)
Scheme 6. Modiﬁcations of indolo[3,2-c]coumarin 7a.
R. A. Irgashev et al. / Tetrahedron Letters 54 (2013) 5734–5738 5737on the use of this approach for the synthesis of other 3-(hetero)aryl-
coumarins containing a nitro group on the 3-(hetero)aryl substitu-
ent are in progress.
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